Loading chat...
TX SB1525
Bill
Status
5/7/2025
Primary Sponsor
Jose Menendez
Click for details
AI Summary
-
Limits health benefit plan issuers to requiring only one prior authorization per year for prescription drugs treating neurodegenerative diseases, adding these conditions to existing protections for autoimmune diseases, hemophilia, and Von Willebrand disease
-
Allows insurers to require an initial prior authorization when an enrollee is prescribed a new medication for a neurodegenerative disease
-
Amends the Insurance Code subchapter heading to include neurodegenerative diseases alongside autoimmune diseases and blood disorders
-
Applies to health benefit plans delivered, issued, or renewed on or after January 1, 2026
-
Takes effect September 1, 2025
Legislative Description
Relating to prior authorization for prescription drug benefits related to the treatment of neurodegenerative diseases.
Health
Last Action
Referred to Insurance
5/8/2025